Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diltiazem
Drug ID BADD_D00674
Description Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization.[L10556] Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle.[T28] Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent [L6289] for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities.[L6289] Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.
Indications and Usage For the treatment of Hypertension
Marketing Status Prescription; Discontinued
ATC Code C05AE03; C08DB01
DrugBank ID DB00343
KEGG ID D07845
MeSH ID D004110
PubChem ID 39186
TTD Drug ID D0OB1J
NDC Product Code Not Available
Synonyms Diltiazem | Cardil | Cardizem | CRD-401 | CRD 401 | CRD401 | Tiazac | Dilacor XR | Dilren | Diltiazem Hydrochloride | Diltiazem Malate | Dilzem | Aldizem | Dilacor
Chemical Information
Molecular Formula C22H26N2O4S
CAS Registry Number 56209-45-1
SMILES CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Nuchal rigidity15.05.04.005; 17.05.02.006--Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Cardiac disorder02.01.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Cardiac fibrillation02.03.02.021--Not Available
Drug intolerance08.06.01.0130.000277%Not Available
Renal impairment20.01.03.0100.000184%Not Available
Cystitis noninfective20.03.02.001--
Lichenoid keratosis23.01.01.004--Not Available
Liver injury09.01.07.022; 12.01.02.003--Not Available
Acute kidney injury20.01.03.0160.000830%
Bladder dysfunction20.03.03.0020.000184%Not Available
Device capturing issue27.01.02.001--Not Available
Medication residue present13.15.01.0320.002029%Not Available
Sinus node dysfunction02.03.03.0170.000184%
Multiple organ dysfunction syndrome08.01.03.0570.000072%
Appendicitis perforated07.04.06.011; 11.01.07.0280.000184%
Grip strength decreased13.15.01.0410.000184%Not Available
Vasoplegia syndrome12.02.01.010; 24.06.03.0110.000184%Not Available
The 10th Page    First    Pre   10    Total 10 Pages